Highlights Ipsen S.A. OTC Markets

Equities

Market Closed - OTC Markets Other stock markets 14:41:09 2024-07-17 EDT			5-day change	1st Jan Change
30.38 ^USD	-0.26%		+2.38%	+3.05%

07-11	CAC40: maintains gains after reassuring US inflation figures	CF
07-11	CAC40: rise without volume, W-Street at its zenith but falls back	CF

CAC40: maintains gains after reassuring US inflation figures	07-11	CF
CAC40: rise without volume, W-Street at its zenith but falls back	07-11	CF
CAC40: over 7600pts before US inflation figures	07-11	CF
Ipsen: worldwide licensing agreement with Foreseen	07-11	CF
Ipsen, Foreseen Biotechnology Ink Exclusive Global Licensing Deal for Antibody-drug Conjugate	07-11	MT
Hutchmed Shares Rise After Tazemetostat Gets Priority Review Status in China	07-05	MT
Ipsen Expands Partnership with Exelixis for Cabometyx	07-02	MT
Ipsen extends collaboration with Exelixis	07-02	CF
IPSEN : UBS remains positive ahead of quarterly results	06-26	CF
Ipsen: share price soars, UBS confirms its recommendation	06-12	CF
IPSEN : UBS remains Buy after FDA approval	06-12	CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis	06-11	CI
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug	06-10	RE
US FDA approves Genfit and Ipsen's liver disease drug	06-10	RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics	06-07	MT
Ipsen: research partnership with Marengo extended	06-07	CF
Ipsen: new positive data in PBC	06-05	CF
Ipsen: mandate to an ISP for share buybacks	06-03	CF
Ipsen: new employee shareholding operation	05-31	CF
Ex-dividend day for final dividend	05-29	FA

No results for this search

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 10:50 am